PET-CT: Principles and Applications (10-Mark Answer)

Definition

Positron Emission Tomography-Computed Tomography (PET-CT) is a hybrid molecular imaging technique that combines functional/metabolic imaging (PET) with anatomical imaging (CT) in a single integrated scanner, allowing fused images that localize areas of abnormal metabolic activity to precise anatomical structures - Grainger & Allison's Diagnostic Radiology.

I. Principles

A. PET Component (Functional Imaging)

PET relies on a radioactive tracer (radiopharmaceutical) that decays by positron emission
The radiotracer is injected intravenously, taken up by cells, and trapped intracellularly after phosphorylation (in the case of glucose analogues); malignant/metabolically active cells trap more tracer than normal cells
Emitted positrons travel a short distance in tissue before colliding with an electron, producing an annihilation reaction
This releases two 511 keV gamma photons at ~180 degrees to each other
These paired photons are detected simultaneously by opposing detectors (coincidence detection), and a computer reconstructs cross-sectional images of tracer distribution - Scott-Brown's Otorhinolaryngology, Head & Neck Surgery, Vol 1

B. CT Component Serves two key functions:

Anatomical localization - precisely maps the site of abnormal tracer uptake, improving diagnostic accuracy and distinguishing pathology from normal physiological uptake
Attenuation correction - corrects for the reduction in PET signal as photons travel through tissue (deeper structures attenuate signal more), giving more accurate quantification of uptake

CT is usually performed at lower radiation dose than diagnostic CT and typically without IV contrast (contrast may cause artefacts), though contrast-enhanced protocols are used in some centers - Scott-Brown's Otorhinolaryngology, Head & Neck Surgery, Vol 1

C. Radiotracers

Most common: 18F-Fluorodeoxyglucose (FDG), a glucose analogue with fluorine-18 substituted at the 2' position; accumulates in tissues with high glycolytic activity (tumors, inflammation, infection)
Others: 18F-sodium fluoride (bone), 11C/18F-choline, 68Ga-DOTATATE (neuroendocrine tumors), 11C-methionine (brain tumors - low background uptake)

D. Image Interpretation

Qualitative (visual assessment of uptake pattern) and semiquantitative analysis using the Standardized Uptake Value (SUV) - normalizes tracer uptake to injected dose and body weight/surface area
Strict protocol consistency (fasting, blood glucose control, uptake time) is essential, especially for treatment response monitoring - Grainger & Allison's Diagnostic Radiology

E. Patient Protocol

Patient fasts (4-6 hours), blood glucose checked (hyperglycemia reduces tumor uptake), tracer injected IV, ~60 minute uptake/rest period in quiet room (minimize muscle/brown fat uptake), then combined PET + low-dose CT acquisition (~20-30 min), arms raised, supine position

II. Applications

A. Oncology (primary use)

Staging: lung cancer (mediastinal nodes, distant metastases), lymphoma, head and neck cancers, esophageal and gastric cancers
Detecting unknown primary in metastatic disease
Characterizing indeterminate pulmonary nodules (sensitivity ~90%, specificity ~83% for malignancy; not useful for nodules <6-10 mm due to false negatives) - Grainger & Allison's Diagnostic Radiology
Response assessment to chemo/radiotherapy (e.g., FDG PET/CT response criteria in lymphoma - Deauville criteria)
Radiotherapy treatment planning - biological tumor volume delineation for IMRT
Restaging and recurrence detection, especially with rising tumor markers (e.g., CA-125 in ovarian cancer) when conventional imaging is equivocal
Post-treatment surveillance (typically performed ≥8 weeks after therapy completion to avoid inflammatory false positives)

B. Cardiology

Myocardial viability assessment (hibernating vs scarred myocardium)
Detection of cardiac sarcoidosis and infective endocarditis/device infection

C. Neurology

Differentiating dementia subtypes (Alzheimer's vs frontotemporal dementia) via glucose metabolism patterns
Epilepsy focus localization (interictal hypometabolism)
Brain tumor grading and recurrence vs radiation necrosis (using amino acid tracers like methionine, since normal brain has low uptake)

D. Infection/Inflammation

Fever of unknown origin, vasculitis (large vessel), osteomyelitis, prosthetic joint/vascular graft infection, sarcoidosis

III. Advantages and Limitations

Advantages	Limitations
Combines functional + anatomical data in one sitting	False positives from inflammation/infection
High sensitivity for detecting metabolically active disease before structural change	False negatives in small lesions (<1 cm), low-grade/mucinous tumors, some renal and low-grade prostate cancers
Improves accuracy of staging, changes management in significant proportion of oncology patients	Radiation exposure (roughly equivalent to two diagnostic CTs)
Better lesion characterization than CT/MRI alone in select settings	High cost, limited availability, need for on-site/nearby cyclotron for short half-life tracers
Guides biopsy and radiotherapy planning	Physiological uptake (brain, myocardium, bowel, brown fat, muscle) can obscure or mimic pathology

Quick Diagram Summary (for exam sketch)

Radiotracer injection → cellular uptake/trapping → positron emission → annihilation (2 x 511 keV photons at 180°) → coincidence detection by ring of detectors → PET data reconstruction + low-dose CT for attenuation correction and localization → fused PET-CT image with SUV quantification.

Recent evidence check: A quick literature check for recent systematic reviews/meta-analyses on FDG-PET/CT (e.g., in NSCLC staging, lymphoma response assessment) found no results that contradict this established textbook framework - the core principles (radiotracer physics, attenuation correction, SUV-based response criteria like Deauville) remain the current standard of practice.

This is a shared conversation. Sign in to Orris to start your own chat.